Intravenous infusion of iPSC-derived neural precursor cells increases acid β-glucosidase function in the brain and lessens the neuronopathic phenotype in a mouse model of Gaucher disease
- 15 October 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 28 (20) , 3406-3421
Abstract
Gaucher disease (GD) is caused by GBA1 mutations leading to functional deficiency of acid-β-glucosidase (GCase). No effective treatment is available for neuronopathic GD (nGD). A subclass of neural stem and precursor cells (NPCs) expresses VLA4 (integrin α4β1, very late antigen-4) that facilitates NPC entry into the brain following intravenous (IV) infusion. Here, the therapeutic potential of IV VLA4+NPCs was assessed for nGD using wild-type mouse green fluorescent protein (GFP)-positive multipotent induced pluripotent stem cell (iPSC)-derived VLA4+NPCs. VLA4+NPCs successfully engrafted in the nGD (4L;C*) mouse brain. GFP-positive cells differentiated into neurons, astrocytes and oligodendrocytes in the brainstem, midbrain and thalamus of the transplanted mice and significantly improved sensorimotor function and prolonged life span compared to vehicle-treated 4L;C* mice. VLA4+NPC transplantation significantly decreased levels of CD68 and glial fibrillary acidic protein, as well as TNFα mRNA levels in the brain, indicating reduced neuroinflammation. Furthermore, decreased Fluoro-Jade C and NeuroSilver staining suggested inhibition of neurodegeneration. VLA4+NPC-engrafted 4L;C* midbrains showed 35% increased GCase activity, reduced substrate [glucosylceramide (GC, −34%) and glucosylsphingosine (GS, −11%)] levels and improved mitochondrial oxygen consumption rates in comparison to vehicle-4L;C* mice. VLA4+NPC engraftment in 4L;C* brain also led to enhanced expression of neurotrophic factors that have roles in neuronal survival and the promotion of neurogenesis. This study provides evidence that iPSC-derived NPC transplantation has efficacy in an nGD mouse model and provides proof of concept for autologous NPC therapy in nGD.Keywords
Funding Information
- Local Initiative for Excellence Foundation
- National Institutes of Health (R01 NS 086134, R21 NS 095047, UH2 NS 092981, R01 NS 103931, R01 DK 36729)
This publication has 88 references indexed in Scilit:
- Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Disease—Links to Parkinson’s DiseaseCell Metabolism, 2013
- Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in SynucleinopathiesCell, 2011
- Stem cell technology for neurodegenerative diseasesAnnals of Neurology, 2011
- Lentiviral Vector Design and Imaging Approaches to Visualize the Early Stages of Cellular ReprogrammingMolecular Therapy, 2011
- Migration of engrafted neural stem cells is mediated by CXCL12 signaling through CXCR4 in a viral model of multiple sclerosisProceedings of the National Academy of Sciences, 2010
- Induced pluripotent stem cells derived from mouse models of lysosomal storage disordersProceedings of the National Academy of Sciences, 2010
- The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonismMovement Disorders, 2009
- Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid β-glucosidase residual activity levelsMolecular Genetics and Metabolism, 2008
- Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's diseaseProceedings of the National Academy of Sciences, 2008
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006